<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023295</url>
  </required_header>
  <id_info>
    <org_study_id>OXC402-201</org_study_id>
    <nct_id>NCT01023295</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)</brief_title>
  <official_title>OXiGENE OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mateon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mateon Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine effects of fosbretabulin tromethamine
      (fosbretabulin) on PCV as reflected by a change from baseline in the number of polypoid
      lesions on indocyanine green angiography (ICGA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate change in number of polypoid lesions on ICGA from baseline to Day 2</measure>
    <time_frame>from baseline to Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate change in the number of polypoid lesions on ICGA from baseline to Day 8</measure>
    <time_frame>from baseline to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the change in area of the branching vascular network of PCV using ICGA from baseline to Day 2</measure>
    <time_frame>baseline to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the change in the area of branching vascular network of PCV on ICGA from baseline to Day 8</measure>
    <time_frame>baseline to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine effects of fosbretabulin on choroidal neovasculariztion (CNV) and total lesion size using fluorescein angiography (FA)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/m^2 fosbretabulin, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/m^2 fosbretabulin, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg/m^2 fosbretabulin, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg/m^2 fosbretabulin, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosbretabulin</intervention_name>
    <description>single dose, intravenous infusion</description>
    <arm_group_label>15 mg/m^2</arm_group_label>
    <arm_group_label>25 mg/m^2</arm_group_label>
    <arm_group_label>35 mg/m^2</arm_group_label>
    <arm_group_label>45 mg/m^2</arm_group_label>
    <other_name>combretastatin</other_name>
    <other_name>CA4P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>single dose, intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female age ≥21 years.

          -  Asian race (e.g. Chinese, Japanese, Korean, Thai).

          -  Polypoidal choroidal vasculopathy in the study eye

          -  Presence of ≥ 1 visible polypoidal varicosity on ICGA.

          -  Presence of a measurable branching vascular network

          -  BCVA by ETDRS of 68 to 4 letters in the study eye.

        Ophthalmologic Exclusion Criteria

          -  Prior treatment with intravitreal or systemic anti-VEGF therapy within 60 days of
             enrollment.

          -  Any other prior treatment for PCV including thermal laser photocoagulation,
             photodynamic therapy (i.e., verteporfin), or any investigational therapies.

          -  Any history of prior retinal or subretinal surgery, transpupillary thermography,
             radiation, implantation of intravitreal drug delivery device, vitrectomy.

          -  Any other intraocular surgery or laser treatment within 90 days or any surgeries
             planned during the study period.

          -  Fibrosis involving ≥50% of the total lesion.

          -  Presence of hemorrhage which potentially obscures &gt;75% of vascular pathology to be
             assessed by imaging procedures.

          -  Retinal or choroidal vascular disease in study eye due to causes other than PCV, such
             as uveitis, trauma, or pathologic myopia.

          -  Macular edema in either eye due to other causes, such as diabetic retinopathy.

          -  Evidence of glaucomatous eye disease, glaucomatous visual field loss.

          -  History of allergy to fluorescein or ICG dye.

        Medical Exclusion Criteria

          -  Current or history within two years of any significant heart disease.

          -  Uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <disposition_first_submitted>October 28, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>October 28, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 1, 2011</disposition_first_posted>
  <last_update_submitted>October 28, 2011</last_update_submitted>
  <last_update_submitted_qc>October 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polypoidal Choroidal Vasculopathy</keyword>
  <keyword>PCV</keyword>
  <keyword>Polypoid</keyword>
  <keyword>oxigene</keyword>
  <keyword>VDA</keyword>
  <keyword>vascular disrupting agent</keyword>
  <keyword>combretastatin</keyword>
  <keyword>fosbretabulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fosbretabulin</mesh_term>
    <mesh_term>Combretastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

